<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2570">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04448756</url>
  </required_header>
  <id_info>
    <org_study_id>MS200569_0026</org_study_id>
    <secondary_id>2020-002248-22</secondary_id>
    <nct_id>NCT04448756</nct_id>
  </id_info>
  <brief_title>M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia</brief_title>
  <acronym>ANEMONE</acronym>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of orally-administered M5049 in COVID-19
      pneumonia participants who are hospitalized but not on mechanical ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">November 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Alive and not Requiring Supplemental Oxygenation</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs)</measure>
    <time_frame>Day 1 through Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Status of Participants on a 9-Point Ordinal Scale</measure>
    <time_frame>Day 1 through Day 60</time_frame>
    <description>A nine point ordinal scale - 0: Uninfected
No limitation of activities
Limitation of activities
Hospitalized, mild disease on, no oxygen therapy
Hospitalized, with oxygen by mask or nasal prongs
Hospitalized, severe disease: noninvasive ventilation or high flow oxygen
Hospitalized, severe disease: intubation and mechanical ventilation
Hospitalized, severe disease: ventilation plus additional organ support - example, vasopressors, Extracorporeal membrane oxygenation (ECMO)
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours on Room Air</measure>
    <time_frame>Day 1 through Day 28</time_frame>
    <description>Normal oxygen exchange in room air.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-Cause Mortality</measure>
    <time_frame>Day 1 through Day 28</time_frame>
    <description>Percentage of Participants who die for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Deterioration: Time to Intensive Care Unit (ICU) Admission</measure>
    <time_frame>Day 1 through Day 28</time_frame>
    <description>Clinical Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Deterioration: Time to Invasive Mechanical Ventilation</measure>
    <time_frame>Day 1 through Day 28</time_frame>
    <description>Clinical Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Deterioration: Time to Non-Invasive Mechanical Ventilation</measure>
    <time_frame>Day 1 through Day 28</time_frame>
    <description>Clinical Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Stay in Intensive Care Unit (ICU)</measure>
    <time_frame>Day 1 through Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Hospitalization Stay</measure>
    <time_frame>Day 1 through Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive and not Requiring Supplemental Oxygenation</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Inflammatory Biomarkers</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cytokine Biomarkers</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Relapse</measure>
    <time_frame>Day 5 through Day 60</time_frame>
    <description>Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Re-Hospitalized</measure>
    <time_frame>Day 5 through Day 60</time_frame>
    <description>Percentage or participants who are re-hospitalized for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Only the first 15 participants will be evaluated for Pharmacokinetic parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Observed Concentration (tmax) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant (Lambda z) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-Life (t1/2) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Normalized Maximum Observed Concentration (Cmax/Dose) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to the Time of the Last Observation (AUC0-t/Dose) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Normalized Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose (AUC0-12h/Dose) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Normalized Area Under the Plasma Concentration-Time Curve From Time of Dosing to Infinity (AUC0-Infinity/Dose) of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for Area Under Plasma Concentration-Time Curve From Time of Dosing to 12 Hours Post-Dose [Racc(AUC0- 12h)] of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for Maximum Observed Concentration [Racc(Cmax)] of M5049</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>M5049 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M5049 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will take M5049 100 milligram (mg) orally each day for 14 days.</description>
    <arm_group_label>M5049 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will take M5049 200 mg orally each day for 14 days.</description>
    <arm_group_label>M5049 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take placebo tablets matched to M5049 daily for 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant provides signed informed consent prior to the initiation of any study
             assessments

          -  Documented test positive (NAT) for SARS-CoV-2 (based on locally acceptable accepted
             guidelines) if sampled within 10 days prior to randomization positive for SARS-CoV-2
             based on locally acceptable guidelines (as per locally accepted guidelines)

          -  Has chest imaging consistent with COVID-19 pneumonia (as per locally accepted
             guidelines)

          -  Not on mechanical ventilation or ECMO

          -  Has an SpO2 less than (&lt;) 94 percent in room air And able to maintain a partial
             pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) greater than or equal to
             (&gt;=) 150 with a maximum FiO2 0.4

          -  Requires hospitalization

          -  Other protocol defined inclusion criteria may apply

        Exclusion Criteria:

          -  Any condition that could interfere with the study objectives, conduct or evaluation in
             the opinion of the Investigator or Sponsor or designee

          -  Any uncontrolled medical illness (eg, cardiovascular disease, hypertension, diabetes
             mellitus, obstructive lung disease, neurological or neuropsychiatric disorder)

          -  Known active infection other than COVID-19

          -  Pregnancy or Breastfeeding

          -  Other protocol defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama-Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>LAC-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sharp Chula Vista Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis University - Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christus Spohn Hospital Corpus Christi-Memorial</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Leforte Morumbi</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alemão Oswaldo Cruz</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Bandeirantes / Hospital Leforte Liberdade</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Emílio Ribas</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200569_0026</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

